US Stock MarketDetailed Quotes

IFRX InflaRx

Watchlist
  • 1.730
  • -0.120-6.49%
Close May 2 16:00 ET
  • 1.750
  • +0.020+1.16%
Post 16:29 ET
117.20MMarket Cap-1.96P/E (TTM)

About InflaRx Company

InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a and its receptor C5aR. Its primary product candidate is Vilobelimab. The company was founded by Niels Christoph Riedemann, Renfeng Guo, and Nicolas Fulpius in December 2007 and is headquartered in Jena, Germany.

Company Profile

SymbolIFRX
Company NameInflaRx
Listing DateNov 8, 2017
Issue Price15.00
Founded2007
CEOProfessor Niels Riedemann
MarketNASDAQ
Employees74
Fiscal Year Ends12-31
AddressWinzerlaer Strasse 2
CityJena
ProvinceThueringen
CountryGermany
Zip Code07745
Phone49-36-41-508180
Websitehttp://www.inflarx.de

Company Executives

  • Name
  • Position
  • Salary
  • Professor Niels Riedemann
  • Executive Director and Chief Executive Officer
  • --
  • Professor Dr. Renfeng Guo, M.D.
  • Executive Director and Chief Scientific Officer
  • --
  • Dr. Thomas Taapken
  • Chief Financial Officer
  • --
  • Dr. Camilla Chong
  • Chief Medical Officer
  • --
  • Derval O’Carroll
  • Senior Vice President and Global Head, Regulatory Affairs and Compliance
  • --
  • Nicolas Fulpius
  • Non-Executive Chairman of the Board
  • --
  • Hege Hellstrom
  • Director
  • --
  • Richard H. Brudnick
  • Independent Director
  • --
  • Mark Kubler
  • Independent Director
  • --
  • Anthony Gibney
  • Independent Director
  • --

Market Insights

Top Gaining Chinese Stocks Top Gaining Chinese Stocks
No. Symbol % Chg
CG MED EQUIP.
838810
+29.98%
BEOKA
870199
+29.96%
Shenzhen Bromake New Material
301387
+20.01%
4
Zhejiang Hongchang Electrical Technology
301008
+20.00%
5
Wuhan Lincontrol Automotive Electronics Co., Ltd.
688667
+20.00%
Log In for the Full List
Unlock Now

Investment Course

Top 5 Industries for Stock Trading under Trump's Second Term
Stocks & Industries to Watch Under Trump's Second Presidency
With mooomoo, find out which stocks and industries may benefit from Trump's second presidency, based on his first administration's track record.

Discussing

Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context, Show More
MicroStrategy Q4 2024 earnings conference call

Reassessing Chinese Assets

Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.